{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:41:53Z","timestamp":1792694513225,"version":"4.5.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Skin cancer is the leading malignancy in immunosuppressed patients, including organ transplant recipients (OTRs), which is increasing in incidence as OTRs live longer. We performed a single-center case series of 4 patients with scalp pleomorphic dermal sarcoma and a history of multiple keratinocyte carcinomas. Outcomes included incidence of dermal sarcoma, dermal sarcoma-related mortality, and histopathologic findings. Out of more than 200 patients followed over a 3-year period in Massachusetts General Hospital High Risk Skin Cancer Clinics, all skin cancer-related deaths (2\/2) were due to metastatic dermal sarcoma. Three of 4 patients diagnosed with scalp dermal sarcoma were OTRs and had been on at least one immunosuppressive medication for a median of 9 years. For patients who died from dermal sarcoma, the median time between diagnosis and death was 6 months. Our findings suggest pleomorphic dermal sarcoma contributes to skin cancer-related morbidity and mortality in OTRs.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac141","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T11:08:39Z","timestamp":1658488119000},"page":"e759-e761","source":"Crossref","is-referenced-by-count":3,"title":["Lethal Dermal Sarcoma in Immunosuppressed Patients"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-4854","authenticated-orcid":false,"given":"Marjan","family":"Azin","sequence":"first","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-8286","authenticated-orcid":false,"given":"Amir H","family":"Ameri","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-8419","authenticated-orcid":false,"given":"Ruth K","family":"Foreman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-6923","authenticated-orcid":false,"given":"Victor A","family":"Neel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1002","authenticated-orcid":false,"given":"Mayra E","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7913-2641","authenticated-orcid":false,"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"},{"name":"Department of Dermatology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"2022090215575606900_CIT0001","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"2022090215575606900_CIT0002","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0041-1345(96)00152-2","article-title":"Skin tumours posttransplantation: a retrospective analysis of 28 years\u2019 experience at a single centre","volume":"29","author":"Webb","year":"1997","journal-title":"Transplant Proc"},{"key":"2022090215575606900_CIT0003","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0041-1345(96)00153-4","article-title":"Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period","volume":"29","author":"Hiesse","year":"1997","journal-title":"Transplant Proc"},{"key":"2022090215575606900_CIT0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/ejso.2001.1119","article-title":"Incidence and clinical course of de-novo malignancies in renal allograft recipients","volume":"27","author":"Winkelhorst","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"2022090215575606900_CIT0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/jlts.2002.29350","article-title":"De novo tumors after liver transplantation: a single-institution experience","volume":"8","author":"Sanchez","year":"2002","journal-title":"Liver Transpl"},{"key":"2022090215575606900_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management","volume":"47","author":"Berg","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2022090215575606900_CIT0007","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0041-1345(96)00152-2","article-title":"Skin tumours posttransplantation: A retrospective analysis of 28 years' experience at a single centre.","volume":"29","author":"Webb","year":"1997","journal-title":"Transplant Proc"},{"key":"2022090215575606900_CIT0008","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D32511046140","article-title":"Pleomorphic dermal sarcoma in a man with hiv: report with next-generation sequencing analysis and review of the atypical fibroxanthoma\/pleomorphic dermal sarcoma spectrum","volume":"25","author":"Chen","year":"2019","journal-title":"Dermatol Online J"},{"key":"2022090215575606900_CIT0009","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1524-4725.2011.02180.x","article-title":"Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience","volume":"38","author":"McCoppin","year":"2012","journal-title":"Dermatol Surg"},{"key":"2022090215575606900_CIT0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-017-0489-6","article-title":"Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma","volume":"18","author":"Soleymani","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"2022090215575606900_CIT0011","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/1097-0142(197306)31:6<1541::AID-CNCR2820310635>3.0.CO;2-6","article-title":"Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases","volume":"31","author":"Fretzin","year":"1973","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/e759\/45667672\/oyac141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/e759\/45667672\/oyac141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T06:00:47Z","timestamp":1676181647000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/9\/e759\/6648488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":11,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,7,22]]},"published-print":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac141","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,7,22]]}}}